MA50670A - Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose - Google Patents
Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible doseInfo
- Publication number
- MA50670A MA50670A MA050670A MA50670A MA50670A MA 50670 A MA50670 A MA 50670A MA 050670 A MA050670 A MA 050670A MA 50670 A MA50670 A MA 50670A MA 50670 A MA50670 A MA 50670A
- Authority
- MA
- Morocco
- Prior art keywords
- antibody compositions
- new formulations
- dose antibody
- stabilize low
- stabilize
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D65/00—Wrappers or flexible covers; Packaging materials of special type or form
- B65D65/38—Packaging materials of special type or form
- B65D65/42—Applications of coated or impregnated materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Mechanical Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762565178P | 2017-09-29 | 2017-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50670A true MA50670A (fr) | 2020-08-05 |
Family
ID=65896542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050670A MA50670A (fr) | 2017-09-29 | 2018-09-28 | Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose |
Country Status (5)
Country | Link |
---|---|
US (2) | US20190099489A1 (fr) |
EP (1) | EP3688033A4 (fr) |
JP (1) | JP2020535181A (fr) |
MA (1) | MA50670A (fr) |
WO (1) | WO2019064263A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA128098C2 (uk) | 2019-02-18 | 2024-04-03 | Елі Ліллі Енд Компані | Водна фармацевтична композиція антитіла проти il-17a |
AU2020368656A1 (en) * | 2019-10-16 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | Vaccine product |
CN115666639A (zh) * | 2020-01-13 | 2023-01-31 | 阿帕特夫研究和发展有限公司 | 用于防止治疗性蛋白吸附到药物递送系统部件的方法和组合物 |
KR20230159887A (ko) * | 2021-03-25 | 2023-11-22 | 쇼오트 파르마 아게 운트 코. 카게아아 | 약학적 용기 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19921303C1 (de) * | 1999-05-07 | 2000-10-12 | Schott Glas | Glasbehälter für medizinische Zwecke |
DE60038386T2 (de) * | 1999-09-08 | 2009-04-23 | Chugai Seiyaku K.K. | Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben |
US8025915B2 (en) * | 2006-01-11 | 2011-09-27 | Schott Ag | Method of preparing a macromolecule deterrent surface on a pharmaceutical package |
WO2007092772A2 (fr) * | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Formulations de protéines |
EP2237038B1 (fr) * | 2007-10-22 | 2015-04-29 | Becton Dickinson and Company | Articles médicaux revêtus d'organopolysiloxane contenant une solution de protéine et tensioactif non ionique |
JP2014500879A (ja) * | 2010-11-16 | 2014-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bcma発現に相関性を有する疾患を治療する因子及び方法 |
AU2012381239B2 (en) * | 2012-05-28 | 2016-05-26 | Namicos Corporation | Glass container and method for manufacturing same |
CN105209069B (zh) * | 2013-03-13 | 2019-08-23 | 豪夫迈·罗氏有限公司 | 抗体配制剂 |
EP3686217A1 (fr) * | 2013-03-15 | 2020-07-29 | GlaxoSmithKline Intellectual Property (No.2) Limited | Formulations d'anticorps à faibles concentrations |
CN104057880B (zh) * | 2014-07-09 | 2016-04-06 | 郑运婷 | 车门防撞装置 |
US10633443B2 (en) * | 2014-09-26 | 2020-04-28 | Macrogenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof |
-
2018
- 2018-09-28 MA MA050670A patent/MA50670A/fr unknown
- 2018-09-28 US US16/145,324 patent/US20190099489A1/en not_active Abandoned
- 2018-09-28 WO PCT/IB2018/057565 patent/WO2019064263A1/fr unknown
- 2018-09-28 EP EP18861358.2A patent/EP3688033A4/fr active Pending
- 2018-09-28 JP JP2020517815A patent/JP2020535181A/ja active Pending
-
2021
- 2021-10-18 US US17/503,759 patent/US20220202937A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3688033A1 (fr) | 2020-08-05 |
US20190099489A1 (en) | 2019-04-04 |
JP2020535181A (ja) | 2020-12-03 |
WO2019064263A1 (fr) | 2019-04-04 |
EP3688033A4 (fr) | 2021-06-23 |
US20220202937A1 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49043A (fr) | Formulation stable d'anticorps | |
CY1122718T1 (el) | Σκευασμα συνδυασμου δυο αντι-ιικων ενωσεων | |
MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
MA49421A (fr) | Formulations d'arn | |
MA46196A (fr) | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal | |
MA56006A (fr) | Formulations sous-cutanées d'anticorps her2 | |
MA50670A (fr) | Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose | |
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
MA45688A (fr) | Compositions et procédés de potentialisation d'agents antimicrobiens | |
MA44391A (fr) | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 | |
FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
MA54052A (fr) | Formulation d'anticorps | |
MA56049A (fr) | Formulations stabilisées contenant des anticorps anti-angptl3 | |
MA54139A (fr) | Formulation d'anticorps | |
MA48461A (fr) | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation | |
AR100453A1 (es) | Composiciones para el cuidado oral que contienen polietilenglicol para estabilidad física | |
MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale | |
MA53466A (fr) | Formulation stable d'anticorps anti-osmr | |
MA55362A (fr) | Formulations stabilisées contenant des anticorps anti-il-33 | |
CL2019001053A1 (es) | Formulaciones farmacéuticas y métodos para prepararlas. | |
MA55033A (fr) | Formulation d'anticorps thérapeutique | |
MA49947A (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes | |
MA45158A (fr) | Composition pharmaceutique comprenant de l'éteplirsen | |
EP3835311C0 (fr) | Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif | |
MA47106A (fr) | Formulations d'anticorps anti-tnf alpha |